Co-Diagnostics, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
CODX$0.29-9.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(21,150,211) | $(26,607,816) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation and amortization | 839,242 | 1,020,143 |
| Stock-based compensation expense | 1,956,078 | 4,116,475 |
| Common stock issued for financial advisory services | 135,000 | - |
| Change in fair value of acquisition contingencies | (684,944) | (194,217) |
| Non-cash lease expense | (4,985) | 12,174 |
| Realized gain on investments | (683,365) | (595,302) |
| Loss from equity method investment | 71,163 | 132,775 |
| (Gain) loss on disposition of assets | 5,004 | (7,013) |
| Provision for credit losses (recoveries of) | (22,375) | 8,262 |
| Inventory obsolescence expense (recovery) | (138,983) | 164,955 |
| Changes in assets and liabilities: | ||
| Accounts receivable | 99,040 | 117,421 |
| Prepaid expenses and other assets | (69,584) | 627,370 |
| Inventory | 121,752 | 233,754 |
| Deferred revenue | 4,700 | (301,972) |
| Income taxes payable | (221,795) | 60,442 |
| Accounts payable, accrued expenses and other liabilities | (3,193,366) | 288,510 |
| Net cash used in operating activities | (22,937,629) | (20,924,039) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (568,078) | (675,365) |
| Proceeds from maturities of marketable investment securities | 33,761,847 | 45,031,967 |
| Purchases of marketable securities | (6,590,939) | (27,408,061) |
| Investment in joint venture | - | (143,750) |
| Net cash provided by investing activities | 26,602,830 | 16,804,791 |
| Cash flows from financing activities | ||
| Issuance of common stock related to at-the-market offering, net of offering costs | 1,313,929 | - |
| Issuance of common stock related to registered direct offering, net of offering costs | 3,528,269 | - |
| Net cash provided by financing activities | 4,842,198 | - |
| Net increase (decrease) in cash and cash equivalents | 8,507,399 | (4,119,248) |
| Cash and cash equivalents at beginning of period | 2,936,544 | 14,916,878 |
| Cash and cash equivalents at end of period | $11,443,943 | $10,797,630 |
| Supplemental disclosure of cash flow information | ||
| Cash paid (received) for income taxes | $1,656 | $(23,350) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.